Home | Disclaimer | Sitemap | Glossary | Library cart | Useful links | Keep me informed | Roche worldwide | Contact webmaster
Search this site
Roche in HIV   News and features   Press releases   Animations   What's new!   Healthcare professionals	Current news Corporate news Archived Press releases UPDATE ON THE MANUFACTURE OF NEW HIV DRUG FUZEON 18-Dec-02 ROCHE RECEIVES FDA CLEARANCE FOR THE COBAS AMPLISCREEN SYSTEM 05-Dec-02 ROCHE RESPONSE TO MSF LETTER 18-Nov-02 NEW DATA INDICATE TREATMENT OF HIV WITH FUZEON SHOULD BE INITIATED BEFORE ALL OTHER TREATMENT OPTIONS DEPLETED 18-Nov-02 FUZEON (ENFUVIRTIDE, T-20) DEMONSTRATES CONSISTENT BENEFIT ACROSS RANGE OF TREATMENT EXPERIENCED HIV PATIENTS 30-Sep-02 REGULATORY FILING IN EUROPEAN UNION FOR FIRST HIV FUSION INHIBITOR FUZEON (T-20) 20-Sep-02 EUROPEAN COMMISSION APPROVES NEW BOOSTED SAQUINAVIR REGIMEN (1000 MG SAQUINAVIR / 100 MG RITONAVIR TWICE DAILY) 19-Sep-02 REGULATORY FILING FOR FIRST HIV FUSION INHIBITOR FUZEON (T-20) 17-Sep-02 ROCHE AND TRIMERIS ANNOUNCE NEXT STEPS IN BRINGING FUZEON (T-20) TO HIV PATIENTS IN NEED OF NEW TREATMENT OPTIONS 02-Aug-02 U.S. FOOD AND DRUG ADMINISTRATION APPROVES NEXT GENERATION HIV-1 TEST 01-Aug-02 FIRST HEAD-TO-HEAD STUDY OF TWO BOOSTED PROTEASE INHIBITORS SHOWS SIGNIFICANT BENEFIT FOR BOOSTED SAQUINAVIR REGIMEN 10-Jul-02 NEW BOOSTED SAQUINAVIR DOSING (1000 MG SAQUINAVIR PLUS 100 MG RITONAVIR BID ) MAINTAINS HIV SUPPRESSION WHILE REDUCING TRIGLYCERIDES AND CHOLESTEROL 10-Jul-02 MAJORITY OF HIV PATIENTS FIND NEW INJECTABLE FUSION INHIBITOR T-20 (ENFUVIRTIDE) EASY TO USE 09-Jul-02 RESEARCHERS IDENTIFY PREDICTIVE AND CLINICAL VALUE OF PROVIRAL HIV-1 DNA QUANTIFICATION FOR HIV PATIENTS 09-Jul-02 NEW T-20 (ENFUVIRTIDE) RESEARCH SIGNALS NEW HOPE FOR CHILDREN AND ADOLESCENTS LIVING WITH HIV 09-Jul-02 FOUR STUDIES EXAMINE STRATEGY OF COMBINING SAQUINAVIR WITH KALETRA� IN TREATMENT-EXPERIENCED HIV PATIENTS 09-Jul-02 TREATMENT EXPERIENCED PATIENTS TWICE AS LIKELY TO ACHIEVE UNDETECTABLE HIV LEVELS WITH T-20 (ENFUVIRTIDE) THAN WITHOUT 08-Jul-02 ROCHE RENEWS ITS COMMITMENT TO THE MULTICENTER AIDS COHORT STUDY 08-Jul-02 ROCHE DIAGNOSTICS SPONSORS SURVEILLANCE PROGRAM TO HELP ENSURE FUTURE PERFORMANCE OF INDUSTRY�S HIV VIRAL LOAD ASSAYS 02-Jul-02 NEW BOOSTED SAQUINAVIR REGIMEN (1000 MG SAQUINAVIR / 100 MG RITONAVIR BID) TO TREAT HIV RECEIVES CPMP POSITIVE OPINION IN THE EU 19-Jun-02 POSITIVE RESULTS FROM SECOND PHASE III STUDY OF HIV FUSION INHIBITOR T-20 (ENFUVIRTIDE) 16-May-02 ROCHE AND TRIMERIS ANNOUNCE 24-WEEK RESULTS FROM FIRST PHASE III STUDY OF HIV FUSION INHIBITOR T-20 18-Apr-02 NEW PROMISING DRUG ADDED TO ROCHE�S STRONG HIV PORTFOLIO 15-Apr-02 STUDY PUBLISHED IN TODAY'S New England Journal of Medicine CONFIRMS ORAL VALCYTE� TREATS AIDS-RELATED EYE DISEASE AS WELL AS IV GANCICLOVIR THERAPY 11-Apr-02 VALCYTE� RECEIVES EU POSITIVE OPINION FOR TREATMENT OF AIDS-RELATED CMV RETINITIS 13-Mar-02 NEW EVIDENCE THAT T-20 ADDS POTENCY TO CONVENTIONAL HIV THERAPIES 19-Feb-02 START OF PILOT PROGRAMME MAY LEAD TO A NEW ERA IN HEALTHCARE DELIVERY FOR AFRICA'S DEVELOPING COUNTRIES 14-Jan-02 A DOUBLE FIRST FOR ROCHE AND TRIMERIS� NEW GROUND-BREAKING HIV FUSION INHIBITORS 19-Dec-01 SWATCH STUDY HIGHLIGHTS IMPORTANCE OF STRATEGIC PLANNING TO OUTWIT HIV RESISTANCE 18-Dec-01 NEW DOSAGE FOR FORTOVASE�/R SHOWS EFFICACY AND EXCELLENT SAFETY PROFILE IN HIV PATIENTS: NEW TREATMENT STRATEGY MAY REDUCE COST OF HIV THERAPY 31-Oct-01 NEW HIV DRUGS - FUSION INHIBITORS - LIKELY TO SUCCESSFULLY TACKLE RESISTANT HIV 30-Oct-01 VALCYTE RECEIVES FIRST EUROPEAN REGULATORY APPROVAL FOR TREATMENT OF AIDS-RELATED CMV RETINITIS 27-Sep-01 PREMIERE HOMOLOGATION EUROPEENNE DE VALCYTE DANS LE TRAITEMENT DE LA RETINITE A CMV LIEE AU SIDA 27-Sep-01 VALCYTE ERSTMALS IN EUROPA F�R DIE BEHANDLUNG DER AIDS-BEDINGTEN CMV-RETINITIS ZUGELASSEN 27-Sep-01 VALCYTE APROBADO POR PRIMERA VEZ EN EUROPA, PARA EL TRATAMIENTO DE LA RETINITIS CITOMEGALOV�RICA RELACIONADA CON EL SIDA 27-Sep-01 ROCHE AND BRAZILIAN MINISTRY OF HEALTH REACH AGREEMENT FOR THE SUPPLY OF HIV DRUG VIRACEPT� 03-Sep-01 ROCHE AND TRIMERIS COMPLETE HIV PHASE III TRIAL RECRUITMENT 09-Aug-01 HIV PATIENTS GIVE GREEN LIGHT TO LONG-TERM USE OF INJECTABLE T-20 11-Jul-01 LARGE VIRACEPT� (NELFINAVIR) STUDY DEMONSTRATES POTENT SUPPRESSION OF HIV AND HIGH PATIENT ADHERENCE OUT TO THREE YEARS OF THERAPY 09-Jul-01 ROCHE AND TRIMERIS BROADEN SCOPE OF HIV PARTNERSHIP 19-Jun-01 NEW DATA REINFORCES BENEFIT OF VIRACEPT IN FIRST LINE THERAPY FOR HIV INFECTION 08-Jun-01 TOP HIV SCIENTISTS MEET TO DISCUSS BETTER LONG TERM TREATMENT OUTCOMES FOR PEOPLE WITH HIV 29-May-01 FOUR STUDIES INVESTIGATE EFFECTIVENESS AND TOLERABILITY OF FORTOVASE�/R AS ONCE- DAILY PROTEASE INHIBITOR FOR HIV INFECTION 09-Apr-01 NEW INITIATIVE CREATES ACCESS TO HIV CARE AND TREATMENT IN FOUR AFRICAN COUNTRIES 28-Feb-01 NEW DATA CONFIRMS HIGHLY EFFECTIVE AND TOLERABLE ROLE OF VIRACEPT� IN FIRST LINE TREATMENT STRATEGIES OF HIV INFECTION 08-Feb-01 ROCHE HIV PROTEASE INHIBITOR SAQUINAVIR SHOWS GREATER IN VITRO POTENCY THAN NEW DRUG LOPINAVIR 23-Oct-00 CALL TO ACTION: ROCHE ADVOCATES DEVELOPMENT OF HIV DRUG POTENCY GUIDELINES TO HELP PHYSICIANS MAKE OPTIMAL TREATMENT DECISIONS 23-Oct-00 IMPORTANT PROGRESS IN TREATMENT OF HIV INFECTION TO BE REPORTED 10-Jul-00 BLOOD LEVELS OF FORTOVASE INCREASE WITH A MINI-DOSE OF RITONAVIR 15-Jun-00 INVESTIGATIONAL AIDS-RELATED ORAL DRUG VALGANCICLOVIR PROVIDES COMPARABLE RESULTS TO INTRAVENOUS CYMEVENE 03-Feb-00 SHIFTING TREATMENT DEMOGRAPHICS HIGHLIGHT NEED TO MANAGE LONG-TERM HIV TREATMENT OPTIONS 02-Feb-00 VIRACEPT COMBINATION IN PREGNANT WOMEN PREVENTS HIV INFECTION IN NEWBORNS, EARLY STUDY SHOWS 02-Feb-00 ROCHE AND TRIMERIS REPORT CLINICAL PROGRESS IN DEVELOPMENT OF HIV FUSION INHIBITORS 01-Feb-00 NEW STUDIES SHOW REAL-LIFE ADVANTAGES OF VIRACEPT IN EFFICACY, TOLERABILITY, DRUG RESISTANCE AND CONVENIENCE 26-Oct-99 VIRACEPT TWICE-DAILY DOSING SHOWS LONG-TERM ANTI-HIV EFFECTIVENESS, STUDY SHOWS 26-Oct-99 NEW FUSION INHIBITOR T-20 COMBINATION REGIMEN REDUCES HIV LEVELS IN HEAVILY PRE-TREATED PATIENTS 25-Oct-99 FORTOVASE ONCE-A-DAY DOSING SHOWS PROMISE IN FIRST STUDY IN HIV-POSITIVE INDIVIDUALS 25-Oct-99 TREATMENT INCLUDING FORTOVASE SHOWS SIGNIFICANT PROMISE TO ELIMINATE HIV TRANSMISSION FROM MOTHER TO INFANT 25-Oct-99 STUDY HIGHLIGHTS POTENTIAL FOR MORE CONVENIENT ONCE-A-DAY ADMINISTRATION 25-Oct-99 BACKGROUND INFORMATION: T-20 FACT SHEET 27-Sep-99 SIXTEEN-WEEK ANALYSIS OF HEAVILY PRE-TREATED PATIENTS RECEIVING T-20 AS A COMPONENT OF MULTI-DRUG SALVAGE THERAPY (T20-205) 27-Sep-99 BACKGROUND INFORMATION: CROSS RESISTANCE DATA PRESENTED AT ICAAC SUPPORT FIRST-LINE USE OF VIRACEPT 27-Sep-99 DATA PRESENTED AT ICAAC SUPPORT FIRST-LINE USE OF VIRACEPT 27-Sep-99 NEW AIDS STUDY SUGGESTS T-20-CONTAINING REGIMENS REDUCES HIV IN HEAVILY PRE-TREATED PATIENTS 27-Sep-99 BACKGROUND INFORMATION: FORTOVASE (Saquinavir) STUDY HIGHLIGHTS POTENTIAL FOR MORE CONVENIENT ONCE-A-DAY ADMINISTRATION 26-Sep-99 STRONG PROMISE FOR ONCE-A-DAY DOSING OF FORTOVASE, STUDY SHOWS 26-Sep-99 ROCHE AND TRIMERIS SIGN AGREEMENT TO DEVELOP TRIMERIS'S COMPOUNDS 12-Jul-99 FUSION INIHIBITORS: BACKGROUND INFORMATION 12-Jul-99 FUSION INHIBITORS:T-20 AND T-1249 BACKGROUND INFORMATION 12-Jul-99 MAJOR ADVANCE IN HIV MANAGEMENT: PAN EUROPEAN HIV GENOTYPING THRUST LAUNCHED 08-May-99 BACKGROUND INFORMATION: FORTOVASE� (SAQUINAVIR): CLINICAL STUDIES HIGHLIGHT NEW FORMULATION'S POWER AND CONVENIENCE 08-May-99 BACKGROUND INFORMATION: GENOTYPING 08-May-99 BACKGROUND INFORMATION: ROCHE VIROLOGY NETWORK AND PE BIOSYSTEMS ANNOUNCE THE GREAT TRIAL 08-May-99
	Home | Disclaimer | Sitemap | Glossary | Library cart | Useful links | Keep me informed | Roche worldwide All information contained in this website is generated and maintained by F. Hoffmann-La Roche, Ltd, Basel, Switzerland. This site is intended for use by physicians only. This site is not intended for residents of the United States of America. Copyright 2006 F. Hoffmann La Roche Ltd. Contact webmaster